As applications of generative AI (GenAI), and AI in general, extend to every industry, the dialogue surrounding its responsible integration remains front and centre.
China has become more accepting of Western medicines and sees the value of a strong patenting process, opening the door for more foreign trade and mutual benefits.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh